Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionJacobs Levy Equity Management, Inc
Latest Disclosed Ownership369,193 shares
Latest Disclosed Value $ 10,968,724
Jacobs Levy Equity Management, Inc reports 37.28% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Jacobs Levy Equity Management, Inc filed a 13F-HR form disclosing ownership of 369,193 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $10,968,724 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 268,926 shares of Travere Therapeutics, Inc.. This represents a change in shares of 37.28% during the quarter. The current value of the position is $16,687,524 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 369,193 100,267 37.28 10,969 6.74 0.0461
2026-02-13 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 268,926 -49,220 -15.47 10,276 35.14 0.0397
2025-11-17 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 318,146 -417,105 -56.73 7,604 -30.13 0.0302
2025-08-14 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 735,251 -127,837 -14.81 10,882 -29.65 0.0427
2025-05-15 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 863,088 -1,311,125 -60.30 15,467 -59.16 0.0613
2025-02-14 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 2,174,213 583,836 36.71 37,875 70.23 0.1340
2024-11-14 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,590,377 -299,467 -15.85 22,249 43.23 0.0858
2024-08-14 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,889,844 765,159 68.03 15,535 79.15 0.0642
2024-05-15 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,124,685 -593,513 -34.54 8,671 -43.86 0.0388
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,718,198 46,428 2.78 15,447 3.35 0.0778
2023-11-17 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,671,770 146,970 9.64 14,946 -36.19 0.0885
2023-08-14 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,524,800 59,048 4.03 23,421 -28.95 0.1350
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 1,465,752 581,490 65.76 32,965 77.26 0.2020
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 884,262 156,148 21.45 18,596 3.65 0.1258
2022-11-15 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 728,114 170,211 30.51 17,941 32.72 0.1418
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 557,903 -367,541 -39.72 13,518 -43.32 0.1046
2022-05-16 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 925,444 -13,648 -1.45 23,849 -18.18 0.1604
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 939,092 -93,306 -9.04 29,149 16.43 0.1952
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 1,032,398 241,467 30.53 25,036 116.95 0.1686
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 790,931 149,759 23.36 11,540 -27.92 0.0782
2021-05-17 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 641,172 -4,878 -0.76 16,010 -9.08 0.1235
2021-02-16 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 646,050 -23,325 -3.48 17,608 42.49 0.1544
2020-11-16 2020-09-30 13F RETROPHIN COM 761299106 669,375 -14,871 -2.17 12,357 -11.51 0.1281
2020-08-17 2020-06-30 13F RETROPHIN COM 761299106 684,246 84,355 14.06 13,965 59.56 0.1512
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 599,891 -24,676 -3.95 8,752 -1.32 0.1125
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 624,567 215,474 52.67 8,869 87.07 0.0870
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 409,093 211,058 106.58 4,741 19.15 0.0582
2019-08-13 2019-06-30 13F RETROPHIN COM 761299106 198,035 45,100 29.49 3,979 14.97 0.0551
2019-05-14 2019-03-31 13F RETROPHIN COM 761299106 152,935 124,319 434.44 3,461 434.10 0.0499
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 28,616 -490 -1.68 648 -22.49 0.0114
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 29,106 1,376 4.96 836 10.58 0.0119
2018-08-14 2018-06-30 13F RETROPHIN COM 761299106 27,730 -1,470 -5.03 756 15.77 0.0119
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 29,200 6,800 30.36 653 38.35 0.0109
2018-02-13 2017-12-31 13F RETROPHIN COM 761299106 22,400 22,400 472 0.0083
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.